首页|期刊导航|中国中医药科技|香草扶正合剂对H22荷瘤小鼠免疫功能及肿瘤组织HuR、BIRC3、NF-κB P65蛋白表达的影响

香草扶正合剂对H22荷瘤小鼠免疫功能及肿瘤组织HuR、BIRC3、NF-κB P65蛋白表达的影响OA

The Effect of Xiangcao Fuzheng Mixture(香草扶正合剂)on the Immune Function of H22 Tumor-Bearing Mice and the Expression of HuR,BIRC3 and NF-κB P65 Proteins in Tumor Tissues

中文摘要英文摘要

目的:探讨香草扶正合剂(xiangcao fuzheng mixture,XCFZ)对 H22 荷瘤小鼠的免疫功能及肿瘤组织 HuR、BIRC3、NF-κB P65 蛋白表达的影响.方法:采用 H22 肝癌细胞株培养移植法建立肝癌荷瘤小鼠模型,随机分为模型组,顺铂(DDP)组,XCFZ 低、中、高剂量组,联合组,每组10 只.造模第2 天开始灌胃给予 XCFZ 低、中、高剂量水溶液,浓度分别为9.3、18.6、37.2 g/kg;顺铂组以5 mg/kg 的顺铂溶液腹腔注射,同时以等量双蒸水灌胃,联合组以 XCFZ 中剂量灌胃和顺铂腹腔注射联合给药,模型组按照等量0.9%氯化钠溶液给药,每天1 次,连续给药14 d 称取小鼠体质量、瘤质量、脾脏及胸腺质量,计算抑瘤率,脾胸腺指数;肿瘤组织 HE 染色;透射电镜观察瘤组织细胞结构;流式细胞术检测 CD3+、CD4+及 CD8+阳性细胞数并计算 CD4+/CD8+比例;ELISA 法检测小鼠血清细胞因子 INF-γ、TNF-α、IL-2、IL-10表达水平;RT-PCR 及Western blot 检测瘤组织中抗原R(HuR)、杆状病毒IAP 重复3(BIRC3)、核转录因子-κB(NF-κB)相关 mRNA 和蛋白表达.结果:与模型组比较,联合组抑瘤率最高,显著优于其余各组,顺铂组去瘤后体质量最轻,联合组优于单纯顺铂组;与顺铂组比较,XCFZ 各剂量组去瘤后体质量显著改善(P<0.05 或 P<0.01).与模型组比较,XCFZ 中剂量组改善脾胸腺指数优于其余各剂量中药组(P<0.05),联合组脾胸腺指数优于顺铂组(P<0.05).模型组肿瘤细胞分布紊乱,多见核分裂及异性肿瘤细胞;XCFZ 各组少见核分裂和异性细胞,多见孤立细胞及胞间空洞,甚至肿瘤细胞核固缩,出现较多肿瘤细胞坏死现象;顺铂组多见碎裂和固缩细胞核及多见胞间空洞,自噬体较多及伴随大量坏死细胞.XCFZ 各剂量给药组组细胞质减少和胞内出现大量空泡.与顺铂组比较,XCFZ 各剂量组和联合组 CD3+和 CD4+含量升高(P<0.05),与模型组比较,XCFZ 各剂量组 CD4+/CD8+显著升高(P<0.05 或 P<0.01),顺铂组显著降低(P<0.05).与模型组比较,XCFZ 各剂量组中剂量组炎症因子表达下降最为显著(P<0.05),且联合组降低各炎症因子表达水平明显优于其余各给药组(P<0.01).与顺铂组比,联合组改善并降低 INF-γ、TNF-α、IL-2、IL-10 表达更为显著(P<0.01).与顺铂组比较,联合组 HuR、BIRC3 和NF-κB P65 mRNA表达降低(P<0.05),其余 XCFZ 各剂量组表达更为显著(P<0.05 或 P<0.01).与模型组比较,中剂量组及顺铂组 HuR、BIRC3 和 NF-κB P65 表达明显降低(P<0.05 或 P<0.01).与顺铂组比较,联合组抑制 HuR、BIRC3 和 NF-κB P65 表达效果更优(P<0.05 或 P<0.01).结论:香草扶正合剂能有效抑制 H22 肝癌荷瘤小鼠肿瘤生长,改善荷瘤小鼠体质量及免疫器官功能,增强 T 淋巴细胞介导的抗肿瘤免疫,其机制可能与抑制 HuR、BIRC3、NF-κB P65 蛋白表达有关.

Objective:To investigate the effects of Xiangcao Fuzheng Mixture(XCFZ)on the immune function and the expression of HuR,BIRC3,and NF-κB P65 proteins in tumor tissues of H22 tumor-bearing mice.Methods:A mouse model of liver cancer with tumor implantation was established using the H22 liver cancer cell line through the transplantation method.The mice were randomly divided into model group,cisplatin group(DDP),the low,medium and high doses of XCFZ groups,the combined group,with 10 mice in each group.From the second day after modeling,the low,medium and high doses of XCFZ were 9.3,18.6 and 37.2 g/kg respectively;the cisplatin group was intraperitoneally injected with 5 mg/kg cisplatin solution,and the same amount of double distilled water was gavaged simultaneously.The combined group was given XCFZ medium dose gavage and cisplatin intraperitoneal injection simultaneously.The model group was given the same amount of 0.9%sodium chloride solution once a day for 14 days.The body weight,tumor weight,spleen and thymus weight of the mice were measured,and the tumor inhibition rate,spleen-thymus index were calculated.The tumor tissue was stained with HE;the cell structure of the tumor tissue was observed under transmission electron microscope;the number of CD3+,CD4+and CD8+positive cells was detected by flow cytometry and the CD4+/CD8+ratio was calculated;the expression levels of serum cytokines(INF-γ,TNF-α,IL-2,IL-10)in mice were detected by ELISA;RT-PCR and Western blot were used to detect the mRNA and protein expressions of human antigen R(HuR),baculoviral IAP repeat containing 3(BIRC3),nuclear transcription factor-κB(NF-κB)in tumor tissue.Results:Compared with the model group,the combination group had the highest tumor inhibition rate and was significantly better than the other groups.The body weight of the mice in the cisplatin group was the lightest after tumor removal,and the combination group was better than the cisplatin group alone.Compared with the cisplatin group,the body weight of the mice in the XCFZ groups at all doses was significantly improved(P<0.05 or P<0.01).Compared with the model group,the medium-dose XCFZ group had a better improvement in the spleen-thymus index than the other XCFZ groups(P<0.05),and the combination group had a better spleen-thymus index than the cisplatin group(P<0.05).In the model group,the tumor cells were distributed disorderly,with many mitotic and atypical tumor cells;in the XCFZ groups,mitosis and atypical cells were rare,with many isolated cells and intercellular cavities,and even nuclear pyknosis and extensive tumor cell necrosis;in the cisplatin group,many fragmented and pyknotic nuclei and intercellular cavities were observed,with many autophagosomes and a large number of necrotic cells.In the XCFZ groups at all doses,the cytoplasm was reduced and many vacuoles appeared in the cells.Compared with the cisplatin group,the CD3+and CD4+contents in the XCFZ groups at all doses and the combination group were increased(P<0.05).Compared with the model group,the CD4+/CD8+ratio in the XCFZ groups at all doses was significantly increased(P<0.05 or P<0.01),and it was significantly decreased in the cisplatin group(P<0.05).Compared with the model group,the expression of inflammatory factors in the medium-dose XCFZ group was the most significantly decreased(P<0.05),and the combination group significantly reduced the expression of inflammatory factors more than the other treatment groups(P<0.01).Compared with the cisplatin group,the combination group significantly improved and reduced the expression of INF-γ,TNF-α,IL-2,and IL-10(P<0.01).Compared with the cisplatin group,the expression of HuR,BIRC3,and NF-κB P65 mRNA in the combination group was decreased(P<0.05),and the expression in the other XCFZ groups at all doses was more significantly decreased(P<0.05 or P<0.01).Compared with the model group,the expression of HuR,BIRC3,and NF-κB P65 in the medium-dose XCFZ group and the cisplatin group was significantly decreased(P<0.05 or P<0.01).Compared with the cisplatin group,the combination group had a better inhibitory effect on the expression of HuR,BIRC3,and NF-κB P65(P<0.05 or P<0.01).Conclusion:Xiangcao Fuzheng mixture can effectively inhibit tumor growth in H22 liver cancer-bearing mice,improve the body weight and immune organ function of the mice,and enhance T lymphocyte-mediated anti-tumor immunity.The mechanism may be related to the inhibition of HuR,BIRC3 and NF-κB P65 protein expression.

程权;毛勇;傅华洲

杭州市第一人民医院·浙江 杭州 310006杭州市第一人民医院·浙江 杭州 310006杭州市第一人民医院·浙江 杭州 310006

香草扶正合剂HuRBIRC3NF-κB P65H22肝癌细胞免疫功能

Xiangcao Fuzheng MixtureHuRBIRC3NF-κB P65H22 liver cancer cellsimmune function

《中国中医药科技》 2026 (2)

103-109,7

浙江省中医药科技计划项目(2026ZL0597)浙江省杭州市卫生科技计划(重点)项目(2018Z02)

评论